ORAL CANCER · REGIONAL SPREAD · LYMPH-NODE RISK
Treatment strategy for cervical lymph node metastases from early-stage tongue and floor of the mouth squamous cell carcinoma using tumour budding and depth of invasion as predictors
Can features already visible in a preoperative biopsy reveal whether an early oral cancer is more likely to spread beyond its primary site?
From local tumour biology to regional spread.
Volume 28 · Article 580 · 2024
DOI: 10.1007/s00784-024-05974-y
ORIGINAL PAPER · AT A GLANCE
Volume 28 · Article 580
Treatment strategy for cervical lymph node metastases from early-stage tongue and floor of the mouth squamous cell carcinoma using tumour budding and depth of invasion as predictors
Ogawa · Yokoo · Yamaguchi · Suzuki · Seki · Shimizu · Makiguchi
Can tumour budding and pathological depth of invasion measured on an incisional biopsy improve preoperative risk stratification of the clinically node-negative neck?
This is a PerioMed-designed bibliographic presentation and critical editorial synthesis, not a reproduction or adaptation of the publisher’s figures or abstract.
FROM LOCAL TUMOUR BIOLOGY TO REGIONAL SPREAD
The tumour begins locally.
The clinical risk changes when it spreads.
Cervical lymph nodes are a major early route of regional spread in oral cancer. A biopsy marker may help identify greater nodal risk, but it does not demonstrate that changing surgery because of that marker improves survival or quality of life.
THE CLINICAL PROBLEM
The neck looks negative.
The risk may not be.
In early oral squamous cell carcinoma, some patients with a clinically node-negative neck harbour occult metastatic disease. Elective neck dissection may treat that risk, but can expose other patients to potentially unnecessary surgery.
The useful question is therefore not whether a marker is associated with aggressive disease, but whether it adds reliable preoperative information to an already complex decision.WHAT IS TUMOUR BUDDING?
Small clusters at the invasive front.
The study defined a bud as an isolated malignant cell or a cluster of fewer than five malignant cells. Pan-cytokeratin immunostaining was used to make buds easier to identify in biopsy sections, particularly where inflammation could obscure them on routine staining.
HOW THE STUDY WAS BUILT
A focused cohort.
A limited number of events.
Early cT1–T2 oral tongue or floor-of-mouth squamous cell carcinoma
A deliberately defined small-tumour population
18.4% developed cervical lymph-node metastasis
Nodal disease identified later during follow-up
Both a budding score of at least five and biopsy-based pathological depth of invasion of at least 5 mm were evaluated separately and together in a composite budding–depth model.
THE MAIN FINDING
Combining the markers changed what the test was good at.
In multivariable analysis, BS ≥5 and pDOI ≥5 mm were each associated with nodal metastasis. The composite model traded sensitivity for higher specificity.
Tumour budding alone
Budding–depth model
Composite BD model in this cohort. Predictive values depend on the prevalence of nodal metastasis in the population being tested.
THE PROGNOSTIC SIGNAL
Five-year disease-specific survival differed by budding score.
These group differences are clinically relevant, but they do not show that changing treatment on the basis of tumour budding improves survival. The study was designed primarily to evaluate risk stratification, not treatment benefit.
FOUR REASONS FOR CAUTION
Before a promising marker becomes a decision rule.
The biopsy must reach the invasive front
A superficial, fragmented or poorly oriented specimen may underestimate both tumour budding and pathological depth of invasion.
Nineteen events are a narrow foundation
The retrospective single-centre analysis included only 19 nodal metastases, limiting model stability and subgroup inference.
Thresholds need external validation
A budding score of at least five and a biopsy pDOI of at least 5 mm should not be treated as universally transportable cut-offs.
Predictive values travel with prevalence
Positive and negative predictive values depend on the selected cohort and may change substantially in another clinical population.
WHAT THE PAPER ALLOWS US TO SAY
Separate the observation
from the clinical leap.
Biopsy tumour budding and pDOI contain preoperative prognostic information.
SUPPORTED IN THIS COHORTThe composite model is more useful for confirming higher risk than excluding occult nodal disease.
SUPPORTED BY THE TEST PROFILEA negative budding–depth profile makes observation safe without rigorous surveillance.
NOT SUPPORTEDChanging treatment because of tumour budding improves survival.
NOT ESTABLISHEDTHE CLINICAL TAKEAWAY
Promising for risk stratification.
Not a stand-alone indication for elective neck dissection.
Tumour budding may complement depth of invasion, imaging and established clinical factors during preoperative discussion. A positive profile may heighten concern, while a negative profile cannot justify complacency or relaxed surveillance.
Before these thresholds can independently influence elective neck treatment, they require prospective multicentre validation, standardised biopsy assessment and evidence that using the marker improves meaningful patient outcomes.
PERIOMED BOTTOM LINE
“The biopsy may carry useful prognostic information—but prediction is not yet a treatment mandate.”
Ogawa and colleagues provide a clinically relevant preoperative signal. The current evidence supports further validation and careful integration, not replacement of established neck-management principles.